The recent case of Leslie Gammon, a North Carolina woman who suffered a GLP-1 overdose, has sparked important conversations about the safety and oversight of telehealth prescriptions for weight loss medications. This incident, and others like it, highlight the potential risks and complexities surrounding the use of GLP-1 drugs, particularly when obtained through telehealth companies.
The Rise of GLP-1 Drugs for Weight Loss
GLP-1 medications have gained popularity among Americans seeking weight loss solutions, with an increasing number of individuals turning to telehealth services for easy access. However, the lack of supervision and proper guidance in these settings has raised concerns about patient safety.
Leslie Gammon's Experience
Leslie Gammon's journey began with a desire to lose weight during menopause. She initially had a positive experience with one telehealth company, losing 18 pounds in four months. However, her second attempt with Amble, another telehealth provider, led to a frightening overdose.
Gammon received a compounded GLP-1 drug and was instructed to inject a significantly higher dose than before. Despite her concerns, she followed the doctor's directions, resulting in severe vomiting and a three-day hospital stay. This incident left her with a $9,000 hospital bill and a sense of responsibility for her own overdose.
Telehealth Oversight and Patient Safety
Dr. Fatima Syed, a medical weight management specialist, emphasizes the importance of clinical oversight for obesity and weight management. She argues that while GLP-1 overdoses can occur even with in-person appointments, the lack of a safety framework in telehealth settings is a cause for concern.
The National Poison Data System reports a significant increase in calls related to GLP-1 overdoses and side effects, with almost 23,000 cases from 2019 to 2025. This trend highlights the need for improved patient education and accessible medical support within the telehealth industry.
Choosing Telehealth Providers
When considering telehealth options for GLP-1 drugs, Dr. Syed advises patients to prioritize companies that offer easy access to medical professionals. She suggests looking for providers who provide clear communication and ongoing support throughout the treatment process.
Additionally, patients should be aware of the difference between brand-name weight loss drugs approved by the FDA and compounded GLP-1 drugs, which are often cheaper but lack FDA safety reviews. Compounded drugs have been associated with accidental overdoses due to confusing measurement units.
Industry Response and Advocacy
Novo Nordisk and Eli Lilly, manufacturers of active ingredients in brand-name GLP-1 drugs, have warned about the risks of mass-compounded knockoffs. They emphasize the potential for these products to be ineffective or even dangerous.
The Alliance for Compounded Pharmacies has called for stronger oversight, transparency, and accountability in the compounding industry, while preserving access to legitimate compounding practices.
Conclusion
The case of Leslie Gammon serves as a reminder of the potential risks associated with telehealth prescriptions for weight loss medications. While convenience is a draw, patients must prioritize their safety and ensure they have access to proper medical guidance and support. The industry's response and advocacy for stronger oversight highlight the need for a balanced approach that considers both patient accessibility and safety.
